World's Best Scientists 2026 revealed!
Kazuyuki Yoshizaki

Kazuyuki Yoshizaki

D-Index & Metrics

Immunology

D-Index
70
Citations
25778
World Ranking
2375
National Ranking
88

Overview

Kazuyuki Yoshizaki is affiliated with Osaka University in Japan and has contributed extensively to the field of medicine. Their research primarily addresses infectious diseases, neurology, oncology, pathology and forensic medicine, and physiology. The scientist's work encompasses 36 publications within medicine, with notable subfields including infectious diseases (12 publications), neurology (7 publications), oncology (6 publications), pathology and forensic medicine (5 publications), and physiology (2 publications).

Their study topics cover several important areas such as COVID-19 clinical research studies and its long-term effects, viral-associated cancers and disorders, lymphoma diagnosis and treatment, SARS-CoV-2 and COVID-19 research, histiocytic disorders and treatments, and eosinophilic disorders and syndromes. This illustrates a focus on both infectious conditions and complex immune-related disorders.

Recent publications by Kazuyuki Yoshizaki include:

  • International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease (2020, Blood Advances)
  • Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease (2021, American Journal of Hematology)
  • Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein (2022, Scientific Reports)
  • Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19 (2021, Frontiers in Medicine)
  • Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease (2023, Nature Communications)

Kazuyuki Yoshizaki has collaborated frequently with several coauthors, including Kazuko Uno (7 publications), Emi E. Nakayama (6 publications), Toshio Tanaka (6 publications), Tatsuo Shioda (6 publications), and Shoji Hashimoto (5 publications). These collaborations highlight an active engagement in multi-author research projects.

The scientist has published in a variety of venues, reflecting the multidisciplinary nature of their research. Frequently targeted journals and platforms include:

  • Scientific Reports (2 publications)
  • Journal of Veterinary Medical Science (2 publications)
  • Research Square (2 publications)
  • Blood Advances (1 publication)
  • American Journal of Hematology (1 publication)

Best Publications

  • Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.

    R Atreya;J Mudter;S Finotto;J Müllberg

  • Structure and function of a new STAT-induced STAT inhibitor

    Tetsuji Naka;Masashi Narazaki;Moritoshi Hirata;Tomoshige Matsumoto

  • Pathogenic Significance of Interleukin-6 (IL-6/BSF-2) in Castleman's Disease

    K Yoshizaki;T Matsuda;N Nishimoto;T Kuritani

  • Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial

    Norihiro Nishimoto;Kazuyuki Yoshizaki;Nobuyuki Miyasaka;Kazuhiko Yamamoto

  • Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

    Norihiro Nishimoto;Yuzuru Kanakura;Katsuyuki Aozasa;Takeshi Johkoh

  • A pilot randomized Trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

    Hiroaki Ito;Masakazu Takazoe;Yoshihiro Fukuda;Toshifumi Hibi

  • TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling

    Christoph Becker;Massimo C. Fantini;Christoph Schramm;Hans A. Lehr

  • Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled, dose‐escalation trial

    Ernest Choy;D A Isenberg;Toby Garrood;S Farrow

  • Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.

    Norihiro Nishimoto;Norihiro Nishimoto;Mitsuko Sasai;Mitsuko Sasai;Yoshihito Shima;Yoshihito Shima;Masashi Nakagawa;Masashi Nakagawa

  • International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

    David C. Fajgenbaum;Thomas S. Uldrick;Adam Bagg;Dale Frank

  • IL-6 Is Required for the Development of Th1 Cell-Mediated Murine Colitis

    Mitsunari Yamamoto;Kazuyuki Yoshizaki;Tadamitsu Kishimoto;Hiroaki Ito

  • Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis.

    Shumpei Yokota;Takako Miyamae;Tomoyuki Imagawa;Naomi Iwata

  • Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

    Hideko Nakahara;Jian Song;Masamichi Sugimoto;Keisuke Hagihara

  • Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.

    Shigeaki Ohno;Satoshi Nakamura;Sadao Hori;Machiko Shimakawa

  • Hypoxic stress induces cardiac myocyte-derived interleukin-6

    Keiko Yamauchi-Takihara;Yoshiji Ihara;Atsushi Ogata;Kazuyuki Yoshizaki

  • Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis

    Nobuhiro Takagi;Masahiko Mihara;Yoichiro Moriya;Norihiro Nishimoto

  • International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

    Frits Van Rhee;Peter Voorhees;Angela Dispenzieri;Alexander Fosså

  • The IL-6R α chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo

    Aysefa Doganci;Tatjana Eigenbrod;Norbert Krug;George T. De Sanctis

  • Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophage-dependent synthesis of BSF-2/IL-6 by T cells.

    Y Horii;A Muraguchi;S Suematsu;T Matsuda

  • Blockade of Interleukin-6 Receptor Suppresses Reactive Astrogliosis and Ameliorates Functional Recovery in Experimental Spinal Cord Injury

    Seiji Okada;M. Nakamura;Y. Mikami;T. Shimazaki

  • TGF-beta suppresses tumor progression in colon cancer by inhibition of IL–6 trans-signaling

    C Becker;MC Fantini;C Schramm;HA Lehr

Frequent Co-Authors

Tadamitsu Kishimoto
Tadamitsu Kishimoto Osaka University
Norihiro Nishimoto
Norihiro Nishimoto Osaka University
Masahiro Iwamoto
Masahiro Iwamoto University of Maryland, Baltimore
Yuichi Yamamura
Yuichi Yamamura Osaka University
Stefan Rose-John
Stefan Rose-John Kiel University
Yoshiyuki Ohsugi
Yoshiyuki Ohsugi Roche (Switzerland)
Markus F. Neurath
Markus F. Neurath University of Erlangen-Nuremberg
Junichi Azuma
Junichi Azuma Osaka University
Satoshi Kimura
Satoshi Kimura University of Tokyo
Hideyuki Okano
Hideyuki Okano Keio University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, several related online degrees can expand career opportunities in healthcare and research. One growing field is psychiatric nursing, with affordable options available through the cheapest online pmhnp programs. These programs prepare graduates to specialize in mental health, complementing immunology knowledge when addressing psychoneuroimmunology.

Nursing professionals pursuing advanced practice roles may consider salary prospects to guide their education choices. Understanding how much do dnp nurses make can help in selecting the right degree and specialization path based on regional demand and compensation.

For those already certified as Family Nurse Practitioners, transitioning to acute care settings is a strategic option. Enrolling in an fnp to acnp bridge program online provides flexible pathways to broaden clinical expertise and work with immunocompromised patients.

Additionally, accelerated routes like the accelerated np programs offer efficient options to complete Nurse Practitioner education online. These programs cater to career changers and fast-track learners seeking to enter advanced practice sooner.

Best Scientists Citing Kazuyuki Yoshizaki

Trending Scientists

Recently Published Articles